- Home
- JRS vs HURA Comparison
JRS vs HURA Comparison
Compare JRS & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | JRS | HURA |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.0M | 131.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JRS | HURA |
|---|---|---|
| Price | $7.62 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 86.6K | ★ 551.9K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.95 | $0.80 |
| 52 Week High | $8.00 | $5.50 |
Technical Indicators
Market Signals| Indicator | JRS | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 22.83 |
| Support Level | $7.63 | $0.81 |
| Resistance Level | $7.70 | $1.07 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 13.02 | 1.72 |
Price Performance
Historical ComparisonAbout JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.